CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
Retrieved on:
Thursday, June 1, 2023
Health, Surgery, Other Health, General Health, Research, Science, Pharmaceutical, Abstract, Stanford University, Section, Survival, C127, Intelligence, Transplant, Congress, MD, Patient, Disease, Kidney, Heart transplantation, Artificial intelligence, Heart failure, Mortality, ATC, Immunosuppression, Caregiver, Biopsy, Dentistry
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations.
Key Points:
- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations.
- CareDx will also be hosting a satellite symposium1 andsponsoring the Women’s Networking Event.
- "We are proud to showcase our leadership with our highest-ever number of abstracts at the 2023 Transplant Congress with data that not only validates the performance of AlloSure® and AlloMap® but also demonstrates their clinical utility in the surveillance and management of patients,” said Reg Seeto, CEO and President of CareDx.
- A combination of AlloSure, serum creatinine and biopsy can improve early detection of subclinical rejection and predict graft failure (C127).